Lite Strategy, Inc. Common Stock (LITS)

• Market cap: $96.2M
• 1 day: -7.57%
• 5 days: -8.44%
• 1 month: -38.83%
• 3 months: 29.65%
• 6 months: 23.63%
• Year to date: 14.9%
• 1 year: -4.25%
• 5 years: -95.45%
• 10 years: -91.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor.

Employees: 28

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

10% more capital invested

Capital invested by funds: $5.85M [Q1] → $6.45M (+$599K) [Q2]

0.91% less ownership

Funds ownership: 40.08% [Q1] → 39.17% (-0.91%) [Q2]

3% less funds holding

Funds holding: 31 [Q1] → 30 (-1) [Q2]

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4